An overarching framework is proposed to guide the design of phase 2 studies in central nervous system disorders. Archetypes are considered for scenarios where dose response is highb rdevant in clinical practice, as in the symptomatic treatment of acute disorders. Archetypes for scenarios where dose response is less rdevant, as in disease modification for neurodqenerative disorders, are beyond the scope of this artide. Primary design archetypes are determined by axes of development that are defined by optimism for success @robability of eficacy) and signal detection (magnitude of the anticipated fled size). The fast-to-registration primary archetype uses a dose-response study as the first eficacy, that is, proof of concept (PoC), study and is appropriate when the prospects for signal detection and the optimism for eficacy are higher. These conditions may exist when the anticipated fled size is large and when either testing a drug with a proven mechanism of action or when a favorable biomarker result was obtained in phase 1. The fast-to-PoC primary archetype tests one dose arm to establish PoC before assessing dose response and is appropriate when the optimism for efficacy and the prospects for signal detedion are lower. lhese conditions may exist when testing a drug with a novel mechanism and/or the anticipated fled size is smaller. Secondary archetypes are used to mitigate the trade-offs between the quick-kill fast-to-PoC approach and the quick-win fastto-registration approach, and are key areas where adaptive designs can be beneficial.
I N T R O D U C T I O N
The focus of this article is on optimizing the design of phase 2 studies of treatments for psychiatric disorders. Phase 2 studies play an important role in drug development because the design of such studies must be optimized in conjunction with optimizing phase 3 and 4 studies, and the phase 2 plan implies that certain goals must be reached in phase 1 to support the subsequent studies. In addition, given that phase 2 is the middle of the three phases required for marketing approval, it is a focal point for achieving objectives sequentially, in parallel, or seamlessly via adaptive approaches.
The usefulness of various phase 2 designs has been extensively examined for some diseases, such as cancer (1, 2) . In psychiatric disorders, there have been elaborate examinations of trial design features, such as blinded lead-in periods (3) (4) (5) (6) . placebo response and its impact on drug-placebo discrimination (7) (8) (9) (10) (11) , assessment scales and sensitivity of scales and subscales (6, (12) (13) (14) (15) (16) (17) (18) , and relationships between other design features, analytic methods, and outcome (6, (19) (20) (21) (22) (23) . as well as general design discussions and examples of novel designs (7.24-27) . However, most of such examinations have used data from or focused on confirmatory studies. Comparatively little has been written about how well certain phase 2 designs inform subsequent trials in psychiatry and other central nervous system (CNS) disorders.
This notwithstanding, the need for improved phase 2 studies is obvious. At present, only about 9% of CNS drugs that enter phase 1 testing survive to launch (28) . Approximately 50% of the failures are a consequence of failures to demonstrate efficacy in phase 2, which is a 15% increase in failure rate over the previous decade (28). Meanwhile, the failure rate of CNS drugs in phase 3 is about 50% (29), with problems in drug-placebo discrimination and increased placebo response growing at an alarming rate (30). These findings suggest that high rates of false negative and false positive results in phase 2 are a major obstacle in CNS drug development. In fact, improving proof-of-concept (PoC) clinical trials has been cited as the most important factor required for reducing the attrition rate in drug development (29) .
In a recent consensus article on the design of PoC trials of antidepressants, the authors concluded that such trials should be small, focusing on a single hypothesis (31). Whether or not this conclusion applies more broadly across psychiatry and CNS disorders and, if so, how then to assess other hypotheses of importance is the motivation for this article. The objective is not to provide specific recommendations for particular disease states or compounds. Rather, the goal is to discuss an overarching framework based on underlying principles that form the basis for individual decisions. The companion articles address specific issues of importance in phase 2 trials: the use of active comparators, first in the context of a positive control to assess assay sensitivity and then as a direct comparison of the test drug versus standard of care.
CONSIDERATIONS I N PHASE 2 DEVELOPMENT
The goals of phase 2 development include: (a) exploring the use for the targeted indication, that is. establishing PoC; and (b) estimating the dosage for subsequent studies, that is, addressing the dose-response relationship (32,33). (Other goals of phase 2, such as assessing safety and tolerability, correlating biomarkers with clinical responses, and so forth, are beyond the scope of this article.) Although there is a large volume of literature on general aspects of assessing dose response (34-40). including applications specific to psychiatry and CNS disorders (41,42), the implications of these considerations on overall drug development have only rarely been addressed (43). Another goal of phase 2 that has emerged in recent years but that is not mentioned in the International Conference on Harmonization guidelines is to provide an early assessment of how the test drug compares with a standard of care. This topic is covered in one of the companion articles.
One way to approach phase 2 development is to achieve each of the goals of establishing PoC and assessing dose response in separate studies. For test drugs that are not effective, sequential studies, which first establish PoC and then only after a positive result proceed to test dose response, can be more efficient. Resources are not wasted studying multiple doses of a test drug, none of which are useful.
However, the sequential approach may also be slow and inefficient for test drugs that are effective. For example, it could take many years to plan and conduct sequential PoC and dosefinding studies in phase 2, and the treatment arms from the PoC study will likely again be tested in the dose-finding study. The sequential study approach might be classified as a cheap quick-kill or slow expensive-win approach.
Another way to approach phase 2 is to conduct a single study focusing on dose finding that is also used to establish PoC. As previously noted, for test drugs that are not effective, this approach is inefficient. But if the drug is effective, more information is obtained sooner and at lower cost than by going through the sequence of PoC, followed by dose finding. Therefore, this approach might be classified as a cheap quick-win, or expensive slow-kill approach.
Therefore, speed and spend (time vs money) must be optimized to produce the best development plan. Implicit in this discussion is that the optimum design for any particular drug hinges on whether or not that drug is effective, a characteristic of course unknown when phase 2 studies are designed because establishing this is one of the objectives. Hence, understanding and mitigating the trade-off between speed and spend is an important aspect of phase 2 development.
How drugs are used in actual clinical practice may also influence phase 2 development. In some scenarios, ample opportunity to fine-tune dosing on an individual patient basis exists. For example, in acute symptomatic treatments to manage chronic diseases such as pain, migraine, depression, anxiety, attention-deficit hyperactivity disorder, and schizophrenia, dosing can start low and go slow; that is, see if a lower dose provides adequate treatment, and if not then try a higher dose (44). The key issue here is that dose response is relevant in the treatment of individual patients.
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In areas where response to treatment is slow, or where the treatment goal is to prevent worsening, such as disease modification treatments for Alzheimer disease, little flexibility may exist to adjust dosing based on efficacy. Therefore, drugs intended to modify the disease and/or delay its progression require long evaluation periods. By the time a patient is identified as not responding adequately to the initial dose, it may be too late to consider alternatives.
This article focuses on those scenarios where dose response is a highly relevant concept in individual patient treatment.
A X E S O F DEVELOPMENT
In scenarios where dose-response is relevant in clinical practice, mitigating the trade-offs between the efficient-kill-inefficient-win of the sequential approach and the inefficient-kill-efficient-win of a dose-finding study as the PoC study is important in developing a successful clinical plan. Optimizing development can be approached by considering two factors, termed here axes of development.
The axes of development are: (a) the optimism for success; and (b) signal detection. Optimism is essentially the probability that the test drug is effective, or has the desired benefit, which we refer to as the probability of efficacy, P(E). Signal detection refers to assay sensitivity, which is the ability of a study to detect a true difference between treatments (45). Not surprisingly, assay sensitivity is strongly influenced by the magnitude of the treatment effect. A third axis, external factors, is also important. External factors are those features not related to the characteristics of the test drug that can influence development decisions. Examples of external forces include logistic and financial considerations, patent expirations, anticipated launches of competitors, and so on.
While the external forces are important, they are mostly idiosyncratic to each compound. Our focus is on the overarching principles that influence all compounds. Hence, external factors are beyond the scope of this article. Therefore, the two key questions to pose when considering development of drugs for which dose response is relevant in clinical practice are:
1. What is the probability that this drug is effective? 2. What is the assay sensitivity for this disease state and drug class?
Although optimism for efficacy can be measured on a continuum as the P(E), it is also useful to categorize optimism as high or low. Optimism may be considered high if the mechanism of action of the test drug has previously been established or if a favorable biomarker result indicative of efficacy has been obtained in phase 1. Optimism might be considered low if the mechanism of action is novel. Of course, there may be other factors that produce a high P(E), such as robust results in a series of validated animal models, even if the mechanism is novel. Likewise, signal detection can also be measured on a continuum based on anticipated effect size. However, it is again useful to categorize this axis as high or low. Although the distinction is arbitrary, a cutoff for high versus low signal detection is chosen as an effect size of 0.5 standard deviations.
With drugs that have comparatively larger effect sizes, assay sensitivity is generally not problematic. Differentiation from placebo can reliably be obtained with smaller sample sizes, and therefore in comparatively smaller and less expensive studies. With drugs that have comparatively smaller effect sizes, differentiation from placebo requires larger sample sizes and assay sensitivity is often considered poor.
Refined discussions of the axes of development should be done based on the continuum. But for gaining an overview of how these factors influence development, the 2 x 2 cross-tabulation of optimism and signal detection as high or low is useful. This categorization is presented in Figure 1 which includes the drug development implication for each of these four categories. For example, with a proven mechanism, it is more likely a beneficial effect (signal) exists than for a novel, unproven mechanism; and if the effect size is large it will be easier to detect the signal. Other points are more subtle, such 
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Optimism as that when the signal is smaller, assessing dose response is likely to be more difficult. To illustrate, consider scenario A where the maximally effective dose yields an effect size of 0.60; in scenario B, the corresponding effect size is 0.30. In scenario A, the dose yielding 50% of the maximal effect by definition has an effect size of 0.3 and the difference between that dose and the maximally effective dose is also an effect size of 0.3. In scenario A, the difference between doses is as great as the difference between the maximally effective dose and placebo in scenario B.
In scenario B, all the differences are small, especially the between-dose differences. Hence, larger sample sizes are required to achieve a commensurate level of reliability on the same evaluation. A dose-ranging study in scenario B would require a large sample size, which might be a poor investment if it were as yet not proven that any of the doses had a beneficial effect.
DESIGN A R C H E T Y P E S
The implications outlined in Figure 1 suggest two primary design archetypes.
1. Fast-to-PoC. This archetype focuses on an inexpensive, quick kill. If optimism is low, the drug is more likely to be ineffective than to be effective. These primary archetypes can be mapped to the axes of development presented in Figure 1 . For example, fast-to-registration fits well for scenarios where signal detection and optimism are both high-the upper right quadrant of Figure  1 . Fast-to-PoC fits well for scenarios where signal detection and optimism are both low-the lower left quadrant of Figure 1 . However, further elaboration is needed to understand how best to map primary archetypes to those scenarios where one of the axes is low and the other is high.
SECONDARY ARCHETYPB One characteristic of a good development plan is minimization of the trade-offs between the primary archetypes. A quick-kill paradigm makes sense if optimism is low, but some of those drugs will be effective. A quick-win paradigm makes sense if optimism is high, but some of those drugs will not be effective. Hence, con- 1. Separate PoC and dose-finding studies in phase 2. This scenario is slow because it employs two sequential trials and is inefficient because treatment arms from the PoC study (high dose and placebo) are repeated in the dose-ranging study. However, this approach discharges risk at low cost because a decision for further development is based o n the first, small trial.
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2. PoC in phase 2. with a dose-finding study in phase 3. Secondary archetypes 1 and 2 involve the same studies. However, the availability of pivotal clinical-trial material or some bridging strategy results in the dose-ranging study in secondary archetype 2 counting as one of the pivotal studies in phase 3 required for regulatory approval.
3. PoC in phase 2, with multiple studies using overlapping doses in phase 3 to assess dose response. This approach can be especially useful when effect sizes are small and therefore the number per arm needed to assess dose response is large.
4. An adaptive phase 2 study, focusing first on PoC and then, after a positive signal is found at an interim analysis, patient allocation is altered to focus on dose finding. This approach can be implemented by initially randomizing only to the maximum dose and placebo, and after the interim then randomizing to placebo and lower doses. However, this plan generates confounding of dose and time. Therefore, it may be more prudent to initially overrandomize to the highest dose but allocate some patients to intermediate and low doses to avoid complete confounding of dose with time. Then, after the positive interim, over-randomize to the intermediate and low doses while keeping the allocation percentage to placebo constant.
Secondary archetypes for a fast-to-registration approach may include the following:
Single dose-finding study in phase 2. This is useful in the high signal detection scenarios when effect sizes are larger. Large effect sizes mean that sample size per arm for a given power is small. The two-to threefold increase in total sample size typically needed for a dose-ranging study versus a PoC trial may be, for example, the difference between total enrollment of 200 patients and 80 patients, respectively. The additional 120 patients may be justifiable to obtain dose response from the same study that establishes PoC, especially if it is likely that the drug is effective. Skip phase 2 altogether. This strategy might be employed when confidence in efficacy is very high, such as when a well-validated biomarker or healthy volunteer model is used in phase 1 to establish PoC (and perhaps also dose response). While such a scenario may be difficult to achieve, the advantages in speed and spend are compelling.
Adaptive phase 2 study focusing first on PoC and then on dose response. This is essentially the same scenario as examined for secondary archetype 4 in the fast-to-PoC primary archetype.
Seamless phase 2/3 study focusing first on dose response, then dropping arms and proceeding to phase 3. This is similar to secondary archetype 1 except that rather than doing separate dose-finding and confirmatory studies, the dose-finding portion seamlessly transitions into the confirmatory phase.
EXAMPLE SCENARIOS
The following example scenarios are illustrations of how to use the axes of development in Dnlg Information Jotunal choosing design archetypes, not specific recommendations. Scenario 1. The test drug is being developed as a potential therapy for the pain associated with diabetic peripheral neuropathy. Results from a validated biomarker in phase 1 have increased optimism for success. The anticipated effect size based on previously approved drugs is greater than 0.50, and there is little evidence in the literature for failed trials. This is the scenario depicted by the upper right quadrant of Figure 1 .
With the positive biomarker result, greater certainty exists that the test drug is effective. With a fairly large effect size, showing dose response with reasonable sample sizes is possible; intermediate doses can contribute to signal detection; and total sample size will not be large. For this scenario, a fast-to-registration archetype using a single dose-finding study in phase 2 may be optimal. Scenario 2. This scenario is the same as scenario 1, except that there is no biomarker and hence with a novel mechanism optimism for efficacy is low, but the anticipated signal, if it exists, is expected to be large. This is the scenario depicted in the upper left quadrant of Figure 1 .
Given that optimism is lower than in scenario 1, greater need exists to focus more heavily on signal detection, but if an effect exists it is likely large, such that the sample size per arm is small and intermediate doses may contribute to signal detection. In this scenario, an adaptive approach that initially over-randomizes to placebo and high dose until the interim analysis (focus on PoC), and then over-randomizes to lower doses (focus on dose response) may be optimal.
Scenario 3. The test drug is being developed as an antidepressant. It has a novel mechanism of action. There is no validated biomarker or healthy volunteer model result from phase 1 to increase optimism for success. The historical effect size for antidepressants is small, and this disease state is well known for high rates of placebo response and poor assay sensitivity, leading to high failure rates of clinical trials. This is the scenario depicted in the lower left quadrant of Figure 1 .
With a novel mechanism, in the absence of other data from a validated biomarker or healthy volunteer model, it is unlikely that the drug will be effective. And even if it is, with a smaller effect size showing a dose response is unlikely, or at least the sample size to do so would be large.
For this scenario, the key idea is to maximize the probability of signal detection given that the signal will be hard to find and that the probability of showing dose response is low. A fastto-PoC primary archetype using a two-arm study, testing a high dose, perhaps via flexible dosing, may be optimal. Dose response can be evaluated in phase 3. using multiple studies with overlapping doses. For example, phase 3 study 1 might contain low dose, middle dose, and placebo: phase 3 study 2 might contain middle dose, high dose, and placebo. Each study has placebo and middle dose. If the designs are as identical as possible, the overlapping doses and similarity in design facilitate pooling and minimize bias in comparing doses across the studies (46). Scenario 4. As in scenario 3, the test drug is being developed as an antidepressant. In this scenario, it is a modified version of an approved compound that is hoped to have better pharmacokinetic properties and fewer drug-drug interactions than the approved compound. Here, in contrast to scenario 3, the mechanism is proven, but the anticipated signal is again small. This is the scenario depicted in the lower right quadrant of Figure 1 .
With a proven mechanism, optimism for success is high, but with a smaller effect size and poor assay sensitivity, demonstrating dose response is unlikely, or at least the required sample size per arm to do so would be large. As in scenario 3. the key idea is to maximize the probability of signal detection given that the signal will be hard to find and given that the probability of showing dose response is low. Hence, the same approach as for scenario 3 may again be appropriate. However, it may also be appropri-
ate to consider the adaptive approach outlined in scenario 2. where initial randomization focuses on signal detection and after a positive interim result randomization is altered to focus on dose response.
D I S C U S S I O N
Improving the quality of PoC studies has been cited as the most important factor in reducing the attrition rate in drug development (29). However, the design of PoC studies is a complex and difficult topic, with many factors that must be addressed. Understanding of fundamental principles may be a useful guide in design decisions to overcome these difficulties.
This article has focused on scenarios such as acute phase clinical trials and symptomatic treatments, where dose response is relevant in treating individual patients. It is proposed that the axes of development, defined by optimism for success and signal detection, provide the overarching framework from which individual design decisions can be made. Although each of these attributes is on a continuum, it is easier to appreciate them in a binary manner as outlined in Figure 1 .
The axes of development lead to primary design archetypes. The key distinction between primary archetypes is whether the first efficacy study should focus on establishing PoC (fast-toPoC) or on evaluating dose response (fast-toregistration). Secondary archetypes are used to minimize the trade-offs between the efficientkill-inefficient-win fast-to-PoC archetype and the inefficient-kill-efficient-win fast-to-registration archetype.
The archetypes presented here are not intended to be an all-encompassing list, but rather a short list of general approaches. The design archetypes are also not intended to provide specific recommendations. Rather, the focus is on the key concepts that provide the overarching framework from which decisions can be made.
External factors, such as logistic and financial considerations, patent expirations, anticipated launches of competitors, and so on, may influence design decisions. These topics were not addressed because they tend to be idiosyncratic to individual development programs. Additional factors not addressed in this article that may influence design decisions include recruitment rate and treatment duration. Nevertheless, the principles outlined may be useful for addressing external and other factors. For example, logistic, financial, or recruitment considerations may limit the size of a study, necessitating a fastto-PoC approach in what would otherwise be a fast-to-registration scenario. The secondary archetypes may be useful in such scenarios to mitigate the trade-off from being forced into a smaller-than-desired first efficacy study.
Adaptive design of clinical trials is a rapidly evolving area that cannot be adequately covered here. Extensive examination of adaptive designs and their relevance to drug development are available (47) . However, as noted in several of the secondary archetypes, adaptive designs may play an important role in PoC trials. For example, an adaptive design may mitigate the trade-offs between a quick-kill fastto-PoC approach and a quick-win fast-to-registration approach. Another example for utility of adaptive designs lies with early comparisons to a standard of care (SoC). An active comparator may be included via an adaptive design, where an interim analysis is conducted when the sample size is sufficient for establishing PoC, or for establishing dose response, depending on the primary archetype: if the interim result is positive, enrollment to placebo, the active comparator, and the relevant doses of the test drug is continued until the desired operational characteristics for the test drug versus SoC contrast has been achieved. This topic is covered in greater detail in one of the companion articles.
The other companion article discusses use of active comparators as a positive control to assess assay sensitivity and other ways to improve assay sensitivity. The issues and use of active comparators either as a benchmark for comparing to SoC or as a positive control can be layered on top of the basic design archetypes discussed here.
C O N C L U S I O N
The proper design of PoC clinical trials includes many challenges, requiring many solutions and approaches. A clear understanding of key overarching principles may be a useful starting point in sorting through t h e many possible approaches for a particular situation. In so doing, t h e axes of development-signal detection and optimism for success-are important considerations that drive design decisions.
